CDK4 and colorectal carcinoma: This has therapeutic implications as piR-823 inhibitor leads to G1 phase stagnation and downregulate cyclin D1 and CDK4 [45], consequently reversing piR-823 role in CRC cell proliferation, and thus it inhibits CRC proliferation and induces cell apoptosis, further cementing piR-823 role in targeted therapy [38].